For US Residents Only

MOVING FORWARD WITH ADCIRCA (tadalafil) ONCE-DAILY

PAH treatment that can help improve exercise ability

ADCIRCA® (tadalafil) is a prescription medication used to treat pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%).

Privacy Policy

This Privacy Policy describes what information we may collect about you; how we use your information; how we protect it; and what choices you have. Health is a very personal, private subject, and we want you to feel as comfortable as possible visiting our various Web sites and using their respective services. This Privacy Policy applies only to websites that directly link to this policy when you click on Dzprivacy policydz in the website footer.

Personally Identifiable Information

United Therapeutics Corporation ("UT") may collect personally identifiable information such as name, address, telephone number, e‐mail address, or other information only when voluntarily submitted by the visitor (i.e. on a web form you fill out and submit). UT uses or discloses personally identified information only with the visitor's consent. UT will comply with any limitations on use communicated when personally identifiable information is collected.

UT will not sell, trade, or rent your personally identifiable information to others. UT may however, share your personally identifiable information with other UT businesses or affiliates, our agents, contractors or business partners in order that they may perform services for us.

UT may use your personally identifiable information for the purposes of sending you information about this website, marketing communications about its products, information about disease states treated with UT’s products, information about support groups for patients and peer givers, educational opportunities, conferences, and seminars, and similar information.

Non‐Personally Identifiable Information

UT collects non‐personally identifiable information in aggregate form to track data such as the total number of visits to our web sites, the number of visitors to each page of our web sites, and the domain names of our visitors' Internet service providers. We use this information, which remains in aggregate form, to understand how our visitors use our web sites so that we may make them better. We may also share this information with our partners or other outside companies. This information is gathered primarily through the use of "cookies." You may be able to change the manner in which your browser manages cookies through your browser’s privacy settings. NO PERSONALLY IDENTIFIABLE INFORMATION IS OBTAINED IN THIS PROCESS.

UT uses third party advertising companies to advertise on our behalf across the Internet. These third parties may collect anonymous information about your visitsto our website, and your interaction with our ads. This is primarily accomplished through technologies including cookies and Action Tags (commonly referred to as a Web Beacons or GIF tags), which are placed on various places within our website. NO PERSONALLY IDENTIFIABLE INFORMATION IS DISCLOSED IN THIS PROCESS.

Security

UT uses technical and organizational security precautions to protect your data from manipulation, loss, destruction or access by unauthorized persons. Any personal data that is provided to UT by you will be secured in transit to prevent its possible misuse by third parties. Our security procedures are revised from time to time based on new technological developments.

Voluntary Disclosures

Any communications or material that you transmit to, or post on, the site by electronic mail or otherwise, including any data, questions, comments, suggestions, or the like, is, and will be treated as, non‐confidential and non‐proprietary information, and UT shall have no obligation of any kind with respect to such information except as otherwise stated in this Privacy Policy.

Links to Other Web Sites

UT web sites may provide links to other web sites as a service to our viewers. These linked web sites are intended to provide helpful information. However, UT does not endorse and is not responsible for the content of third‐party sites. Nor does UT have any control over the information you may choose to provide these sites. This Privacy Policy does not apply to linked sites.

Changes to Privacy Policy

Any changes to this Privacy Policy will be communicated promptly on this page. Please check back periodically.

Important Safety Considerations for ADCIRCA® (tadalafil)

  • You should discuss all of your medical conditions and all medications with your healthcare provider before starting ADCIRCA
  • Do not take ADCIRCA if you take any medications that contain nitrates (often used for chest pain) or any guanylate cyclase stimulators (for example riociguat Adempas®), as the combination could cause a sudden, unsafe drop in blood pressure
  • Do not take ADCIRCA if you are allergic to tadalafil or any other ingredient in ADCIRCA
  • If you experience chest pain after taking ADCIRCA, contact your healthcare provider
  • ADCIRCA is a type of medication called a phosphodiesterase 5 inhibitor (PDE-5i). PDE-5is can cause blood vessels to widen, which may result in a decrease in blood pressure. If you have heart-disease or any problems with low blood pressure, tell your healthcare provider before taking ADCIRCA, as these conditions may be affected by the action of ADCIRCA
  • If you have ever had blockage in the veins of your lungs, known as pulmonary veno-occlusive disease (PVOD), ADCIRCA is not recommended for you
  • Taking ADCIRCA with alcohol, or blood pressure medications, such as alpha-blockers, may lower blood pressure and cause hypotension (light-headedness or fainting)
  • Do not take ADCIRCA if you are taking rifampin (an antibiotic for certain bacterial infections), or antifungal medications, such as ketoconazole and itraconazole. If you require treatment with both ADCIRCA and ritonavir (Norvir®) at the same time, your dose of ADCIRCA will need to be adjusted. Inform your healthcare provider if you have kidney or liver problems before taking ADCIRCA
  • ADCIRCA contains the same ingredient (tadalafil) as Cialis®, which is used to treat erectile dysfunction (ED, impotence) and the signs and symptoms of benign prostatic hyperplasia (BPH, enlarged prostate). If you are taking ADCIRCA, do not take Cialis or other PDE-5is
  • In rare cases, patients reported side effects such as decreased eyesight or loss of vision in one or both eyes (NAION), or sudden decrease or loss of hearing, sometimes with ringing in the ears and dizziness. If you experience any of these side effects after taking ADCIRCA, seek medical attention right away
  • In rare cases, men taking PDE-5is (including tadalafil) for erectile dysfunction reported side effects such as an erection lasting more than four hours. If you experience a prolonged erection, seek medical attention right away
  • The most common side effects of ADCIRCA are headache, muscle pain, getting red or hot in the face (flushing), nausea, pain in the arms, legs or back, upset stomach, stuffy or congested nose

ADC.ISI.CON.KCGLB-4-108.v1

For more information about ADCIRCA, please see the Full Prescribing Information and
Patient Information or call 1-800-545-5979.

Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.

Important Safety Considerations for ADCIRCA® (tadalafil)

  • You should discuss all of your medical conditions and all medications with your healthcare provider before starting ADCIRCA
  • Do not take ADCIRCA if you take any medications that contain nitrates (often used for chest pain) or any guanylate cyclase stimulators (for example riociguat Adempas®), as the combination could cause a sudden, unsafe drop in blood pressure
  • Do not take ADCIRCA if you are allergic to tadalafil or any other ingredient in ADCIRCA
  • If you experience chest pain after taking ADCIRCA, contact your healthcare provider
  • ADCIRCA is a type of medication called a phosphodiesterase 5 inhibitor (PDE-5i). PDE-5is can cause blood vessels to widen, which may result in a decrease in blood pressure. If you have heart-disease or any problems with low blood pressure, tell your healthcare provider before taking ADCIRCA, as these conditions may be affected by the action of ADCIRCA
  • If you have ever had blockage in the veins of your lungs, known as pulmonary veno-occlusive disease (PVOD), ADCIRCA is not recommended for you
  • Taking ADCIRCA with alcohol, or blood pressure medications, such as alpha-blockers, may lower blood pressure and cause hypotension (light-headedness or fainting)
  • Do not take ADCIRCA if you are taking rifampin (an antibiotic for certain bacterial infections), or antifungal medications, such as ketoconazole and itraconazole. If you require treatment with both ADCIRCA and ritonavir (Norvir®) at the same time, your dose of ADCIRCA will need to be adjusted. Inform your healthcare provider if you have kidney or liver problems before taking ADCIRCA
  • ADCIRCA contains the same ingredient (tadalafil) as Cialis®, which is used to treat erectile dysfunction (ED, impotence) and the signs and symptoms of benign prostatic hyperplasia (BPH, enlarged prostate). If you are taking ADCIRCA, do not take Cialis or other PDE-5is
  • In rare cases, patients reported side effects such as decreased eyesight or loss of vision in one or both eyes (NAION), or sudden decrease or loss of hearing, sometimes with ringing in the ears and dizziness. If you experience any of these side effects after taking ADCIRCA, seek medical attention right away
  • In rare cases, men taking PDE-5is (including tadalafil) for erectile dysfunction reported side effects such as an erection lasting more than four hours. If you experience a prolonged erection, seek medical attention right away
  • The most common side effects of ADCIRCA are headache, muscle pain, getting red or hot in the face (flushing), nausea, pain in the arms, legs or back, upset stomach, stuffy or congested nose

ADC.ISI.CON.KCGLB-4-108.v1


For more information about ADCIRCA, please see the Full Prescribing Information and
Patient Information or call 1-800-545-5979.

-Thomas A Gieseke - 3 illustrations for Adcirca: pillbox with empty "Sunday" compartment, isolated dog and isolated pedometer. Indefinite buyout of rights for use in print and electronic media (iPad presentation) for use by Adcirca only -Copyright Clearance Center - Wolters Kluwer Health, Circulation, Nazzareno Galie, Bruce H. Brundage, Hossein A. Ghofrani, Ronald J. Oudiz, Gerald Simmonneau, Zeenat Safdar, Shelley Shapiro..., Tadalafil Therapy for Pulmonary Arterial Hypertension, License No: 3177700012726 -Nicholais Photography - Unlimited use of photos in print, digital, web for pro and consumer in the US -Bella Agency - Victoria Gardner, unlimited use in print, digital and web